Skip to content

Beam Therapeutics

US · BEAM #2614 by market cap Listed 2020
20.90 -0.04 -0.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 20.51 -2.05%
After-hours 21.66 +3.65%
Overnight 20.82 -0.57%
37.9220.6520.902026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on BEAM?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -12.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 25.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D

How much profit the business keeps from each dollar of sales and capital.

Operating margin -274.6% Better than 5%
Net margin -57.2% Better than 8%
Return on equity -8.1% Better than 21%
Return on invested capital -7.0% Better than 20%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -29.8% Better than 18%
6-month return -27.0% Better than 21%
12-month return (ex latest month) 8.3% Better than 44%
Distance below 52-week high 45.4% Better than 23%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 13.1x Better than 95%
Debt to assets 10.4% Better than 69%
Interest coverage -417.9x Better than 3%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 91.7% Better than 75%
Upside to average target 136.2% Better than 89%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -8.45%
1M -16.17%
3M -26.38%
6M -22.91%
YTD -24.60%
1Y +1.46%
3Y -32.05%
5Y -76.70%

Key statistics

Price & volume

Prev close
20.94
Open
20.60
Day range
20.54 - 22.10
Avg price
21.07
Volume
3.89M
Turnover
81.89M
Amplitude
7.45%
52-week range
20.44 - 38.26

Valuation

P/E
-25.80
P/E (TTM)
-23.75
P/B
2.27
EPS
-0.81
Net profit
-83.83M
Net assets
952.68M

Share structure

Market cap
2.16B
Float cap
1.92B
Shares out
103.50M
Float shares
91.86M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-02-06
52-week range 3% of range
20.44 38.26

45.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-8.43M net over the window

Short interest

Shares short
26.08M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Beam Therapeutics (BEAM)?

Beam Therapeutics last traded at 20.90. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Beam Therapeutics's market cap?

About 2.16B.

What is the P/E ratio of Beam Therapeutics?

The trailing twelve-month P/E is -23.75. The Valuation tab shows it against the stock's own five-year range.

Does Beam Therapeutics pay a dividend?

Beam Therapeutics does not currently pay a regular dividend.

Is Beam Therapeutics a buy according to analysts?

The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 49.36, which implies 136.2% upside from the current price. This is not investment advice.

What is Beam Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Beam Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:41 · For reference only, not investment advice and not tailored to your situation.

Beam Therapeutics discussion 0 comments

Add a comment